As a consequence, DNA damage sensitivity of BRM- or BRG1-deficient cells correlates with GTF2H1 protein levels, which could, potentially, be used to select SWI/SNF-deficient cancers that are more sensitive to platinum drug chemotherapy. Here, GTF2H1 is linked to cancer.